Incannex Healthcare March 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement

Clinical stage pharmaceutical development company, Incannex
Healthcare Limited (ASX: IHL) (NASDAQ: IXHL), (‘Incannex’ or the ‘Company’), is pleased to provide its
quarterly activities report and appendix 4C for the period ended 31 March 2023. Incannex is undertaking a
multitude of U.S. Food and Drug Administration (‘FDA’) research and development (‘R&D’) programs for
cannabinoid pharmaceutical products and psychedelic medicine therapies administered by health
professionals.